Recruiting NA INTERVENTIONAL 1-arm
NCT07270601
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis (LYNX)
Development and Diagnostic Evaluation of a Novel Quantifiable Ultrasound Based Multi-parametric Biomarker for Hepatic Steatosis in Patients With Suspected MASLD ( LYNX )
Sponsor: ContextVision AB
Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease NAFLD - Non-Alcoholic Fatty Liver Disease
Interventions
EchoSense FibroScan Philips 3T Ingenia Elition Philips EPIQ Elite Verasonics NXT Data Acquisition System
Updated 1 time since 2026 Last updated: Nov 26, 2025 Started: Nov 17, 2025 Primary completion: Oct 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07270601, this NA trial focuses on MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and NAFLD - Non-Alcoholic Fatty Liver Disease and remains actively recruiting participants. Sponsored by ContextVision AB, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- ContextVision AB
- University of Washington
Data source: ContextVision AB
For direct contact, visit the study record on ClinicalTrials.gov .